BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25154026)

  • 1. Reaction coupling between wild-type and disease-associated mutant EZH2.
    Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
    ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
    Sneeringer CJ; Scott MP; Kuntz KW; Knutson SK; Pollock RM; Richon VM; Copeland RA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20980-5. PubMed ID: 21078963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
    Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
    FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
    Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
    ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
    Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
    PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of EZH1 and EZH2 in development and cancer.
    Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
    BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
    Wigle TJ; Knutson SK; Jin L; Kuntz KW; Pollock RM; Richon VM; Copeland RA; Scott MP
    FEBS Lett; 2011 Oct; 585(19):3011-4. PubMed ID: 21856302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
    Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
    Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
    Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
    Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
    Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
    Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrations of EZH2 in cancer.
    Chase A; Cross NC
    Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.